Contemporary Patterns of Medicare and Medicaid Utilization and Associated Spending on Sacubitril/Valsartan and Ivabradine in Heart Failure

IMPORTANCE: In 2015, the US Food and Drug Administration approved 2 new medications for treatment of heart failure with reduced ejection fraction, sacubitril/valsartan and ivabradine. However, few national data are available examining their contemporary use and associated costs. OBJECTIVE: To evalua...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:JAMA Cardiol
Autori principali: Sumarsono, Andrew, Vaduganathan, Muthiah, Ajufo, Ezimamaka, Navar, Ann Marie, Fonarow, Gregg C., Das, Sandeep R., Pandey, Ambarish
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Medical Association 2020
Soggetti:
Brief Report
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6865331/
https://ncbi.nlm.nih.gov/pubmed/31738371
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamacardio.2019.4982
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi